Pacific Shuanglin Bio-pharmacy Hits Day Low Amid Price Pressure at CNY 12.83

Pacific Shuanglin Bio-pharmacy Co., Ltd. experienced a significant decline today, with the stock dropping by 5.2% as it reached an intraday low of CNY 12.83. This performance is notably below the China Shanghai Composite, which fell by 3.63% during the same period. Over the past week, the stock has seen a 9.0% decrease, and its one-month performance reflects a decline of 4.0%. In the broader context, Pacific Shuanglin has faced considerable challenges, with a year-to-date performance of -5.41% and a staggering 23.09% drop over the past year, contrasting sharply with the 13.33% gain of the China Shanghai Composite. The company's financial metrics indicate a decline in net sales by 16.23%, alongside a low operating cash flow of CNY 78.7 million and a return on capital employed (ROCE) of just 7.06%. As a large-cap player in the pharmaceuticals and biotechnology sector, Pacific Shuanglin's recent performance underscores its struggle to keep pace with market trends, raising concerns about its financial health and market position.